Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.

Sofia BruniFlorencia L MauroCecilia Jazmín ProiettiRosalia I Cordo-RussoMartin A RivasGloria InurrigarroAgustina DupontDario RochaElmer A FernándezErnesto Gil DezaDaniel Lopez Della VecchiaSabrina BarchukSilvina FigurelliDavid LassoAdrián D FriedrichMaría C SantilliMaría V ReggeGabriel LeberszteinClaudio LevitFabiana AnfusoTeresa CastiglionePatricia V ElizaldeMaria F MercoglianoRoxana Schillaci

Published in: Journal for immunotherapy of cancer (2023)

These findings provide rationale to pursue sTNFα blockade combined with trastuzumab or trastuzumab drug conjugates for MUC4+ and HER2+ breast cancer patients to overcome trastuzumab resistance.

Keyphrases

epidermal growth factor receptor
metastatic breast cancer
positive breast cancer
tyrosine kinase
rheumatoid arthritis
cell proliferation
clinical trial
emergency department
cancer therapy
oxidative stress
endoplasmic reticulum stress
adverse drug